Usmani, Saad Z.
Khan, Imran
Chiu, Christopher
Foureau, David
Druhan, Lawrence J.
Rigby, Katherine
Casneuf, Tineke
Sasser, A. Kate
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma
https://doi.org/10.1007/s40262-023-01232-8
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
https://doi.org/10.1016/s0140-6736(15)01120-4
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
https://doi.org/10.1186/s40164-018-0096-7
Funding for this research was provided by:
Janssen Research & Development, LLC
Article History
Received: 11 December 2017
Accepted: 2 February 2018
First Online: 7 February 2018